C

Cellivery Therapeutics Inc
KOSDAQ:268600

Watchlist Manager
Cellivery Therapeutics Inc
KOSDAQ:268600
Watchlist
Price: 6 680 KRW -29.91% Market Closed
Market Cap: ₩594.9m

Operating Margin

-60.9%
Current
Improving
by 186.8%
vs 3-y average of -247.6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-60.9%
=
Operating Income
₩-14.9B
/
Revenue
₩24.5B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-60.9%
=
Operating Income
₩-14.9B
/
Revenue
₩24.5B

Peer Comparison

Country Company Market Cap Operating
Margin
KR
Cellivery Therapeutics Inc
KOSDAQ:268600
594.9m KRW
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
236.9B USD
Loading...
US
Danaher Corp
NYSE:DHR
165.5B USD
Loading...
CH
Lonza Group AG
SIX:LONN
37.6B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
40.1B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
279.2B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
38.2B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
46.3T KRW
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
28.8B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
20.3B EUR
Loading...

Market Distribution

Lower than 93% of companies in Korea
Percentile
7th
Based on 2 615 companies
7th percentile
-60.9%
Low
-163 055.6% — -2.2%
Typical Range
-2.2% — 6.8%
High
6.8% — 22 874.8%
Distribution Statistics
Korea
Min -163 055.6%
30th Percentile -2.2%
Median 2.7%
70th Percentile 6.8%
Max 22 874.8%

Cellivery Therapeutics Inc
Glance View

Cellivery Therapeutics, Inc. engages in the research and development of medicine and pharmacy. The company is headquartered in Seoul, Seoul. The company went IPO on 2018-11-09. The firm develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The firm research and develop therapeutic drug candidates such as Parkinson’s disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity & type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs).

Intrinsic Value
Not Available
C
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-60.9%
=
Operating Income
₩-14.9B
/
Revenue
₩24.5B
What is Cellivery Therapeutics Inc's current Operating Margin?

The current Operating Margin for Cellivery Therapeutics Inc is -60.9%, which is above its 3-year median of -247.6%.

How has Operating Margin changed over time?

Over the last 3 years, Cellivery Therapeutics Inc’s Operating Margin has increased from -6 563.8% to -60.9%. During this period, it reached a low of -6 563.8% on Aug 30, 2021 and a high of -60.9% on Oct 30, 2024.

Back to Top